Skip to main content
OpenTrials
Completed

NCT Number: NCT03139903

The Primordial Dwarfisms: Diagnosis, Identification of the Molecular Basis of Seckel Syndrome and Microcephalic Osteodysplastic Primordial Dwarfism Type II

The purpose of this study si to define morphological and epidemiological parameters and identify new symptoms in French patients with Seckel syndrome (SCKL) or microcephalic osteodysplastic primordial dwarfism type II (MOPDII).

Completed

Looking for future studies?

Notify Me

Key information

Age range

2 month and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Medical Genetics Department and INSERM U781, Necker-Enfants Malades Hospital

Paris, 75743, France

About this study

Multicentre study, aiming to determine morphological and epidemiological parameters and identify new symptoms in French patients with SCKL or MOPDII.

At pre-inclusion visit: Realization of the photographs of: the face, entire body and the extremities (hands and feet) that will be serve for the collegiate decision of the inclusion or not of patients.

Patients are seen at inclusion V1 , a second visit V2 at 6-10 months after V1 and an annual follow-up visit.

At inclusion:

  • Full Clinical Examination, specialized consultations (Otorhinolaryngology, stomatology, orthopedics, ophthalmology)
  • Results of x-ray examinations and biological tests
  • Assessment of the patients competencies and initiation of appropriate care ( orthophony and psychomotricity...)
  • Assessment of intelligence and cognitive ability according the WISC-IV scale
  • Blood testing for diagnosis and research.

Visit 2:

  • Full Clinical Examination
  • Cerebral angiography-MRI for all patients
  • Programming a neurosurgery / neurovascular consultation based on MRI results
  • Immuno-hematology and hepato-gastroenterology consultation if anomaly during the visit V1

Annual follow-up visit:

  • Assessment of the complications of the disease and its clinical care
  • Full clinical examination
  • Skeletal x-ray and systematic orthopedic consultation
  • Blood Check
  • Prescription of tests if necessary depending to the complications identified of the disease
  • Reevaluation of the care according to the detected symptoms

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients aged from 2 months to 50 years must present all of the following criteria:

  • Symmetrical intrauterine growth restriction (IUGR) < - 2 DS, Birth size <-2 DS and Cranial perimeter of birth <-2 DS
  • Postnatal growth restriction (size <-4DS)
  • Microcephaly <-4DS
  • Clinical Diagnosis of Seckel Syndrome or Microcephalic osteodysplastic primordial dwarfism type II (MOPDII) by a geneticist
  • Having given free and informed consent

Exclusion criteria

  • Refutation of the diagnosis
  • Parents' refusal to participate in genetic studies once the diagnosis of SCKL or MOPDII has been establish for the patient (major or minor)
  • Allergy to gadolinium, contraindicating the realization of an Angio-MRI
  • Absence of affiliation to a social security scheme or Universal Health Coverage.

Treatment and study plan

Primary outcomes

  1. to visualize any vascular abnormalities according the cerebral angiography-MRI

    Time frame: 10 months

Secondary outcomes

  1. Assessment of intelligence and cognitive ability according the Wechsler Intelligence Scale for Children (WISC-IV)

    Time frame: 2 days

  2. Measurement of visual acuity

    Time frame: 2 days

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Official study title

The Primordial Dwarfisms: Diagnosis, Identification of the Molecular Basis of Seckel Syndrome and Microcephalic Osteodysplastic Primordial Dwarfism Type II (MOPDII).

Acronym: NANPIM

Important dates

Study start
2010
Primary completion
2013
Study completion
2015
First posted
May 4, 2017
Registry last updated
Nov 20, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.